PROFESSOR PATENT: GLP-1 WAR ROOM
Neuro-symbolic wargaming across the $150B+ GLP-1 patent landscape (Semaglutide & Tirzepatide). Automating 35 U.S.C. § 103 Otsuka obviousness, § 112(a) Amgen v. Sanofi full-scope enablement sieves, and MCTS peptide design-arounds with All-Elements Rule immunity.
Concentric 5-Layer Thicket & Hatch-Waxman Expiration Radar
Every pharmaceutical franchise surrounds its drug substance with layered rings of patents. Our AST compiler resolves the exact statutory base expirations, Patent Term Extensions (PTE under 35 U.S.C. § 156), and pediatric exclusivities to uncover the real commercial cliffs.
US 8,114,833
Propylene glycol-containing peptide formulations
STATUTORILY EXPIRED: Expired March 20, 2026. Generic filers no longer restricted from propylene glycol.
US 10,335,462
Use of long-acting GLP-1 peptides
ROUTINE CLINICAL TITRATION (35 U.S.C. § 103): 1.0 mg dose is nested in WO 2006/097537 (0.1–5.0 mg/week). Prima facie obvious under In re Peterson.
US 8,129,343
Acylated GLP-1 compounds
FATAL AMGEN OVERBREADTH & OTSUKA OBVIOUSNESS: Claim 1 lacks full-scope enablement (Amgen score 3.84). Claim 4 obvious over Liraglutide + Deacon + Kurtzhals.
US 9,474,780
GIP and GLP-1 co-agonist compounds
POS 20 SPECIFICITY: Claim 1 requires C20 diacid acylation at position 20 with dual Aib2/Aib13. Readily design-aroundable via modified linker relocation.
US 11,357,820
Tirzepatide pharmaceutical formulations
BUFFER/TONICITY RESTRICTION: Claims specific NaCl + dibasic sodium phosphate buffer at pH 6.5–7.5. Easily bypassed via organic histidine/citrate matrices.
Hatch-Waxman 30-Month Litigation Stay Simulator (21 U.S.C. § 355(j))
When a generic ANDA filer files a Paragraph IV certification, the patentee has 45 days to file suit, triggering an automatic 30-month statutory injunction.